TY - JOUR T1 - Radiation Pneumonitis After Volumetric Modulated Arc Therapy for Non-small Cell Lung Cancer JF - Anticancer Research JO - Anticancer Res SP - 5793 LP - 5802 DO - 10.21873/anticanres.15396 VL - 41 IS - 11 AU - MASAYUKI FUJIWARA AU - HIROSHI DOI AU - MASATAKA IGETA AU - HITOMI SUZUKI AU - KAZUHIRO KITAJIMA AU - MASAO TANOOKA AU - TOSHIHISA ISHIDA AU - TSUKASA WAKAYAMA AU - TAKASHI YOKOI AU - KOZO KURIBAYASHI AU - TAKASHI KIJIMA AU - MASAKI HASHIMOTO AU - NOBUYUKI KONDO AU - SEIJI MATSUMOTO AU - SEIKI HASEGAWA AU - NORIHIKO KAMIKONYA AU - KOICHIRO YAMAKADO Y1 - 2021/11/01 UR - http://ar.iiarjournals.org/content/41/11/5793.abstract N2 - Background/Aim: To evaluate the incidence and grade of radiation pneumonitis after volumetric modulated arc therapy (VMAT) performed for the treatment of non-small cell cancer (NSCLC). Patients and Methods: Fifty consecutive non-surgical candidates with NSCLC underwent VMAT. Thirty-five patients had stage-III tumors and 15 had recurrent tumors. The prescribed radiation dose for the gross tumor and the elective nodal area was 69 Gy in 30 fractions and 51 Gy in 30 fractions, respectively. Results: Radiation pneumonitis developed in 38 patients (76%, 38/50), and grade ≥2 radiation pneumonitis developed in 11 patients (22%, 11/50). The percentage of lung volume that received a dose in excess of 5 Gy (V5), V10, V20, V30, and the mean lung dose (MLD) in the bilateral and ipsilateral lung were significantly associated with the development of grade ≥2 radiation pneumonitis. Conclusion: The incidence and degree of radiation pneumonitis are acceptable following treatment of NSCLC with VMAT. ER -